Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07822984). This is a study registration, not published results. Lead sponsor: Fudan University. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 374 participants (ESTIMATED). Conditions: EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer). Interventions: DRUG: Third-generation EGFR tyrosine kinase inhibitor; DRUG: Platinum plus pemetrexed chemotherapy; DRUG: Pemetrexed maintenance therapy; RADIATION: Consolidative stereotactic radiotherapy. Primary outcome measures: Progression-Free Survival (PFS) , 4 years. Brief summary: This national multicenter, randomized controlled clinical trial evaluates the safety and efficacy of consolidative stereotactic radiotherapy in patients with advanced EGFR-mutant non-small cell lung cancer who have oligo-residual disease after four cycles of first-line treatment with third-generation EGFR-TKI plus platinum-based pemetrexed chemotherapy. Eligible participants will be randomized 1:1 to continue third-generation EGFR-TKI plus pemetrexed maintenance therapy alone or to receive stereotactic radiotherapy to all oligo-residual lesions in addition to the same maintenance therapy. The primary endpoint is progression-free survival.